South Korea’s Financial Supervisory Service (FSS) concluded that Genencell used misleading claims about Indian clinical-trial approval during its 2020–2021 COVID-19 drug development efforts, including a claim that helped drive a 29.9% one-day rise in Philooks, which had invested in Genencell. FSS records said the Indian procedures concerned designation of the drug as a natural product, not approval for a COVID-19 treatment, and that the drug was not under consideration by India’s Central Drugs Standard Control Organization (CDSCO). Separately, Yoo Chul-woo, U&D, Chairman Namgoong Gyeon and Lee Jae-chul’s Time Investment appeared in Genencell-linked investments before major developments and exits immediately afterward. Time Investment acquired a 6.46% Gold Pacific stake through 4 billion Korean won of convertible bonds in September 2020 and later sold about one-third after Genencell announced Indian trials. In 2021, investors sold their entire fund stakes one day after October 27 clinical-trial approval from South Korea’s Ministry of Food and Drug Safety, at about 5,000 won per share for an estimated return of at least 25% after stock splits. The timing does not by itself establish wrongdoing, while FSS also examined Sejong Medical and related activity involving broker Yang. Genencell’s pipelines ultimately failed in development.